A decade in drug discovery.

摘要

"The current challenges facing the pharmaceutical industry are unprecedented in its history. Perhaps foremost among these are the industry's lower revenue growth, poor stock performance, the lowest number of new chemical entity (NCE) approvals and the poor late-stage R&D pipelines prevalent throughout the industry." As we look back on 10 years of publishing the journal, it is apparent that this evaluation of the pharmaceutical landscape could have resonated with readers familiar with the field at any time during the past decade. In fact, it comes from an article analysing the status of the industry near the beginning of this period, which posed the question of whether the pharmaceutical industry could reduce the attrition rates that have led to soaring R&D costs and to a lack of new drugs to compensate for the huge loss of revenues as older blockbusters fall over the patent cliff.